Methods: In a randomized controlled trial, 52 healthy obese individuals were, after a diet-induced 12% body weight loss, randomized to treatment with or without administration of the GLP-1RA liraglutide (1.2 mg per day)
38 Grauslund et al identified all patients with diabetes in Denmarks national health registry and found that semaglutide was an independent predictor of incident NAION (HR = 2.19)
Dosing often follows a gradual titration process to help minimise side effects and allow the body to adjust
In comparison, AOD-9604 appears to result in weight loss, primarily related to fat loss
JAMA Research Letter Links Semaglutide To Gastroparesis Risk A 2023 research letter in JAMA found that users of weight loss medications semaglutide and liraglutide, the active ingredient in Victoza and Saxenda, experienced gastroparesis nearly three times as often as those on bupropion-naltrexone (Contrave), another weight-loss drug